{"id":544257,"date":"2021-05-21T19:28:01","date_gmt":"2021-05-21T19:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544257"},"modified":"2021-05-21T19:28:01","modified_gmt":"2021-05-21T19:28:01","slug":"oropharyngeal-cancer-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/oropharyngeal-cancer-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544257.html","title":{"rendered":"Oropharyngeal Cancer Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Oropharyngeal<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cOropharyngeal Cancer \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Oropharyngeal Cancer, historical and forecasted epidemiology as well as the Oropharyngeal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Oropharyngeal Cancer – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>”.<\/p>\n

DelveInsight’s “Oropharyngeal Cancer – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Oropharyngeal Cancer, historical and forecasted epidemiology as well as the  Oropharyngeal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    According to the Search Results Surveillance, the estimated number of Oral cavities & pharynx was near to 53,260 for 2020 (for both sexes)<\/p>\n<\/li>\n

  2. \n

    As per the Surveillance, approximately 1.2% of men and women will be diagnosed with oral cavity and pharynx cancer at some point during their lifetime (based on 2015–2017 data).<\/p>\n<\/li>\n

  3. \n

    As per studies the average age of diagnosis of Oropharyngeal Cancer is 62. Moreover,  near to 25% of cases occur in people younger than 55. Nonetheless, these cancers are rare in children.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Oropharyngeal Cancer market report covers a descriptive overview and comprehensive insight of the Oropharyngeal Cancer epidemiology and Oropharyngeal Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. The Oropharyngeal Cancer market report provides insights on the current and emerging therapies.<\/p>\n

    3. Oropharyngeal Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Oropharyngeal Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Oropharyngeal Cancer market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/oropharyngeal-cancer-market<\/span><\/a>
    <\/strong><\/p>\n

    Oropharyngeal Cancer: Overview<\/strong><\/p>\n

    Cancer specific to the oropharynx is called oropharyngeal cancer-a type of head and neck cancer that accounts for around thousands of newly diagnosed cases in the US every year. The leading cause of head and neck cancers is smoking tobacco, and as smoking has become less common in recent years, so has the occurrence for most head and neck cancers. The exception to this is oropharyngeal cancer, which is drastically increasing, especially in the younger population. The earliest stage oral cavity or oropharyngeal cancers are called stage 0 (carcinoma in situ), and then range from stages I through IV. As a rule, the lower the number, the less the cancer has spread. A higher number, such as stage IV, means cancer has spread more.<\/p>\n

    The key players involved in the Oropharyngeal Cancer market:<\/strong><\/p>\n

      \n
    1. \n

      ISA Pharmaceuticals and Regeneron Pharmaceuticals<\/p>\n<\/li>\n

    2. \n

      Precigen<\/p>\n<\/li>\n

    3. \n

      Monopar Therapeutics<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Oropharyngeal Cancer treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        ISA101b plus Cemiplimab<\/p>\n<\/li>\n

      2. \n

        PRGN-2009<\/p>\n<\/li>\n

      3. \n

        Validive<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/oropharyngeal-cancer-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Oropharyngeal Cancer Patient Share (%) Overview at a Glance<\/p>\n

        5. Oropharyngeal Cancer Market Overview at a Glance<\/p>\n

        6. Oropharyngeal Cancer Disease Background and Overview<\/p>\n

        7. Oropharyngeal Cancer Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Oropharyngeal Cancer<\/p>\n

        9. Oropharyngeal Cancer Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Oropharyngeal Cancer Emerging Therapies<\/p>\n

        12. Oropharyngeal Cancer Market Outlook<\/p>\n

        13. Country-Wise Oropharyngeal Cancer Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Oropharyngeal Cancer Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Oropharyngeal Cancer – Pipeline Insights, 2021<\/strong><\/p>\n

        “Oropharyngeal Cancer Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oropharyngeal Cancer market. A detailed picture of the Oropharyngeal Cancer pipeline landscape is provided, which includes the disease overview and  Oropharyngeal Cancer treatment guidelines.<\/p>\n

        Oropharyngeal Cancer – Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Oropharyngeal Cancer- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Oropharyngeal Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cOropharyngeal Cancer \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Oropharyngeal Cancer, historical and forecasted epidemiology as well as the Oropharyngeal Cancer market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544257","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544257"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544257\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}